Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis

Summary

The purpose of this study is to determine whether AN2898 and AN2728 ointments are safe and effective treatments for mild-to-moderate atopic dermatitis (AD).

Timeline

Start

2011-05

Primary completion

2011-11-11

Completion

2011-11-11

Outcome

Met primary endpoint

registry NUMBER AN2898 Ointment, 1% + Ointment Vehicle: Greater Decrease in Active Lesion: 71.4 percentage of participants NCT01301508 ↗

registry analysis (superiority or other test); AN2898 Ointment, 1% + Ointment Vehicle; p = 0.008; Two-sided sign test; NCT01301508 ↗

registry NUMBER AN2728 Ointment, 2% + Ointment Vehicle: Greater Decrease in Active Lesion: 68.0 percentage of participants NCT01301508 ↗

registry analysis (superiority or other test); AN2728 Ointment, 2% + Ointment Vehicle; p = 0.017; Two-sided sign test; NCT01301508 ↗

Publications

• Murrell DF, Gebauer K, Spelman L, Zane LT. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study. J Drugs Dermatol. 2015 Oct;14(10):1108-12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AN2898	Unknown	1 %	Topical
Subject	Crisaborole	Small molecule	2 %	Topical

Indications